Article thumbnail

Reassortment and Mutations Associated with Emergence and Spread of Oseltamivir-Resistant Seasonal Influenza A/H1N1 Viruses in 2005–2009

By Ji-Rong Yang, Yu-Cheng Lin, Yuan-Pin Huang, Chun-Hui Su, Je Lo, Yu-Lin Ho, Ching-Yuan Yao, Li-Ching Hsu, Ho-Sheng Wu and Ming-Tsan Liu

Abstract

A dramatic increase in the frequency of the H275Y mutation in the neuraminidase (NA), conferring resistance to oseltamivir, has been detected in human seasonal influenza A/H1N1 viruses since the influenza season of 2007–2008. The resistant viruses emerged in the ratio of 14.3% and quickly reached 100% in Taiwan from September to December 2008. To explore the mechanisms responsible for emergence and spread of the resistant viruses, we analyzed the complete genome sequences of 25 viruses collected during 2005–2009 in Taiwan, which were chosen from various clade viruses, 1, 2A, 2B-1, 2B-2, 2C-1 and 2C-2 by the classification of hemagglutinin (HA) sequences. Our data revealed that the dominant variant, clade 2B-1, in the 2007–2008 influenza emerged through an intra-subtype 4+4 reassortment between clade 1 and 2 viruses. The dominant variant acquired additional substitutions, including A206T in HA, H275Y and D354G in NA, L30R and H41P in PB1-F2, and V411I and P453S in basic polymerase 2 (PB2) proteins and subsequently caused the 2008–2009 influenza epidemic in Taiwan, accompanying the widespread oseltamivir-resistant viruses. We also characterized another 3+5 reassortant virus which became double resistant to oseltamivir and amantadine. Comparison of oseltamivir-resistant influenza A/H1N1 viruses belonging to various clades in our study highlighted that both reassortment and mutations were associated with emergence and spread of these viruses and the specific mutation, H275Y, conferring to antiviral resistance, was acquired in a hitch-hiking mechanism during the viral evolutionary processes

Topics: Research Article
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:3069057
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2009). Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans.
  2. (1989). Biologic potential of amantadineresistant influenza A virus in an avian model.
  3. (1987). Children with influenza A infection: treatment with rimantadine.
  4. (2006). Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use.
  5. (2010). Effect of the neuraminidase mutation H274Y conferring resistance to oseltamivir on the replicative capacity and virulence of old and recent human influenza A(H1N1) viruses.
  6. (2009). Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa.
  7. (2006). Emergence of drug-resistant influenza virus: population dynamical considerations.
  8. (2010). Emergence of H274Y oseltamivir-resistant A(H1N1) influenza viruses in Japan during the 2008–2009 season.
  9. (2008). Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe.
  10. (2008). Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir.
  11. (2010). Epidemiological, antigenic and genetic characteristics of seasonal influenza A(H1N1), A(H3N2) and B influenza viruses: basis for the WHO recommendation on the composition of influenza vaccines for use in the 2009–2010 Northern Hemisphere season.
  12. (2008). Genetic and epidemiological analysis of influenza virus epidemics in Taiwan during
  13. (2007). Immunization by avian H5 influenza hemagglutinin mutants with altered receptor binding specificity.
  14. (2005). Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern.
  15. (2009). Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States.
  16. (2009). Influenza A virus resistance to oseltamivir and other antiviral medicines. Available: http://www.who.int/csr/disease/influenza/2008-9nhemisummaryreport/en/index.html. Accessed
  17. (2009). Influenza A(H1N1) virus resistance to oseltamivir - 2008/2009 influenza season, northern hemisphere. Available: http://www.who.int/csr/ disease/influenza/H1N1webupdate20090318%20ed_ns.pdf. Accessed
  18. (2007). MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0.
  19. (2009). Morbidity and mortality associated with nosocomial transmission of oseltamivirresistant influenza A(H1N1) virus.
  20. (2007). Neuraminidase inhibitor resistance in influenza viruses.
  21. (2001). Oral oseltamivir treatment of influenza in children.
  22. (2005). Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic.
  23. (2009). Oseltamivir-resistant influenza A(H1N1) viruses detected in Europe during season 2007–8 had epidemiologic and clinical characteristics similar to cocirculating susceptible A(H1N1) viruses.
  24. (2010). Oseltamivir-resistant influenza A(H1N1) viruses in south of France,
  25. (2010). Oseltamivirand amantadine-resistant influenza virus A (H1N1).
  26. (2009). Oseltamivirand amantadine-resistant influenza viruses A (H1N1).
  27. (2009). Oseltamivirresistant influenza viruses A
  28. (2010). Permissive secondary mutations enable the evolution of influenza oseltamivir resistance.
  29. (1991). Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine.
  30. (2007). Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide.
  31. (2007). The evolution of epidemic influenza. Nat Rev Genet 8: 196–205. Oseltamivir-Resistant Influenza
  32. (2007). The genesis and spread of reassortment human influenza A/H3N2 viruses conferring adamantane resistance.
  33. (2002). The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo.
  34. (2008). The Influenza Virus Resource at the National Center for Biotechnology Information.
  35. (1991). Two signals mediate nuclear localization of influenza virus (A/WSN/33) polymerase basic protein 2.